FDA批准了Nuvo的局部麻醉霜
- 互联网2012年11月5日 15:41 点击:1849
美国食品和药物管理局(FDA)批准了Nuvo的一种补充型新药Pliaglis(利多卡因/丁卡因)7%。用于局部皮肤镇痛麻醉。
FDA approves Nuvo anesthetic topical cream
PBR Staff Writer Published 23 October 2012
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Nuvo Research's Pliaglis (lidocaine/tetracaine) 7%/7% cream.
Pliaglis, a topical local anesthetic cream forms a pliable peel on the skin and is used on skin of adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal.
Nuvo has licensed global marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialised in dermatology.
Galderma Laboratories US and Canadian operations president Francois Fournier said, "Pliaglis offers a pre-treatment solution and contributes to improving the patient experience of an aesthetic treatment."
Nuvo Pain Group president Bradley Galer said, "Pliaglis is an important part of Nuvo's expanded topical pain product portfolio."
联系邮箱:kefu@labbase.net
版权与免责声明
- 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。